BR

BrightPath Biotherapeutics Co., Ltd.

Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. The company's pipeline encompasses multiple platforms, including cancer peptide vaccines, immuno-modulators, and advanced cell therapies. A primary focus is its proprietary iPS-NKT platform, a novel allogeneic cell therapy that uses natural killer T-cells (NKT cells) derived from induced pluripotent stem cells (iPSCs) for cancer treatment. This technology enables the large-scale, homogeneous production of NKT cells, which are naturally rare. The company, formerly known as GreenPeptide, also develops peptide vaccines like GRN-1201, which has progressed to clinical trials. Its business model covers drug discovery, research, and early-phase clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:34
Registration Form
確認書
Japanese 8.9 KB
2025-11-14 07:34
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 198.0 KB
2025-06-20 09:01
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB
2025-06-19 08:36
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 08:32
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-19 08:25
Registration Form
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 933.5 KB
2024-11-08 07:35
Interim Report
確認書
Japanese 9.0 KB
2024-11-08 07:34
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 224.9 KB
2024-06-21 09:07
Registration Form
訂正有価証券届出書(組込方式)
Japanese 254.0 KB
2024-06-21 08:34
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-21 08:33
Registration Form
確認書
Japanese 9.0 KB
2024-06-21 08:32
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 990.5 KB
2024-06-19 08:00
Registration Form
有価証券届出書(組込方式)
Japanese 513.9 KB
2024-02-09 07:12
Report Publication Announcement
確認書
Japanese 9.1 KB
2024-02-09 07:11
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 195.3 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clear Channel Outdoor Holdings, Inc. Logo
An OOH ad platform connecting brands to consumers via digital billboards and data analytics.
United States of America
CCO
CODEXIS, INC. Logo
Engineering high-performance enzymes for pharma, diagnostics, and life science manufacturing.
United States of America
CDXS
Cogent Biosciences, Inc. Logo
Developing precision small molecule therapies for cancers, autoimmune, and rare diseases.
United States of America
COGT
COMPASS Pathways plc Logo
Developing psilocybin therapies for severe mental health challenges like TRD and PTSD.
United States of America
CMPS
COMSCORE, INC. Logo
Cross-platform audience measurement and media analytics for advertisers, publishers, and agencies.
United States of America
SCOR
COPRO-HOLDINGS. Co., Ltd. Logo
Dispatches technical personnel to Japan's construction & plant industries.
Japan
7059
Corbus Pharmaceuticals Holdings, Inc. Logo
Clinical-stage oncology company developing targeted therapies like ADCs for cancer and obesity.
United States of America
CRBP
Corvus Pharmaceuticals, Inc. Logo
Develops novel, targeted therapies for immune diseases and cancer.
United States of America
CRVS
Coya Therapeutics, Inc. Logo
Developing Treg-modulating therapies for neurodegenerative and autoimmune diseases.
United States of America
COYA
A creator agency connecting professionals in creative, tech, medical, and legal sectors.
Japan
4763

Talk to a Data Expert

Have a question? We'll get back to you promptly.